According to a recent report published by Grand View Research, the global CBD pet market grew to US$195.9 million in 2022. North America holds the largest revenue share by far, at 40.5%, and the Asia Pacific market is expected to expand the fastest through 2030, at 33%. Suffice to say, business is booming all over the world when it comes to CBD products in the pet space (and the human space, for that matter).
But the regulatory landscape remains something of a maze to navigate, especially in North America. At the end of January 2022, the U.S. Food and Drug Administration (FDA) announced that “after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals' desire for access to CBD products with the regulatory oversight needed to manage risks.” At the same time, the FDA also denied three citizen petitions asking the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements in the human space. Additionally, said the FDA, “CBD also poses risks to animals, and people could be unknowingly exposed to CBD through meat, milk and eggs from animals fed CBD. Because it is not apparent how CBD products could meet the safety standard for substances in animal food, we also do not intend to pursue rulemaking allowing the use of CBD in animal food. A new regulatory pathway could provide access and oversight for certain CBD-containing products for animals.”
